Tenderwize
Retour à la recherche

Contrats-cadres pour des thérapeutiques innovantes contre les maladies infectieuses

Health and Digital Executive Agency (HaDEA) , HADEA - Health and Digital Executive Agency·Brussels, Belgium·EUR 252M·Expired · Sep 02, 2026·Neg W Call·Services·Framework
High valueStructured notice only
Titre original de l'avis

Belgium – Research and development services and related consultancy services – Multiple sourcing Framework Contracts to speed up the development of and access to innovative medical countermeasures Next Generation Therapeutics for Infectious Diseases

72/100

Score d'opportunité

Needs reviewHigh complexity
ServicesFrameworkExpired
Pourquoi ce score ?

Opportunité

72 / 100

Complexité

88 / 100

Facteurs de risque

The procurement documents appear available through the Funding and Tenders Portal, but their extracted content was not...

The full exclusion grounds and any selection requirements are deferred to procurement documents and are not specified i...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
Health and Digital Executive Agency (HaDEA) , HADEA - Health and Digital Executive Agency
Pays
Belgique
CPV
73000000 - Research and development services and related consultancy services +1 autres
Date limite
Sep 02, 2026
Valeur estimée
EUR 252M

Aperçu

Moderate opportunity

Faits clés

  • EUR 252M estimated value
  • Framework procurement
  • Services contract
  • 2 lots
  • Development of innovative next-generation therapeutics for infectious diseases under competitive development phases within a Pre-Commercial Procurement model.
  • Potential treatment areas include viral infections, infection-related acute respiratory distress syndrome, and sepsis.
Afficher le résumé complet

HaDEA is procuring two EU-funded framework service lots under a competitive phased Pre-Commercial Procurement procedure for innovative next-generation therapeutics for infectious diseases. The scope includes pathogen-targeted and host-targeted therapeutics, combination therapies, alternative administration routes, and therapies addressing viral infections, infection-related ARDS or sepsis. The total estimated value is EUR 252,000,000. Electronic submission through the Funding and Tenders Portal is required by 2 September 2026 at 14:00:59 UTC. The opportunity is substantial but requires detailed review of procurement documents that were not provided or analyzed.

Risques

The procurement documents appear available through the Funding and Tenders Portal, but their extracted content was not...

The full exclusion grounds and any selection requirements are deferred to procurement documents and are not specified i...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The procurement uses a competitive development in phases under Pre-Commercial Procurement and is structured as framework contracts.

Administrative

  • Two lots are available and the notice states that a tenderer may submit for and be awarded a maximum of two lots.
  • Electronic submission is required through the Funding and Tenders Portal submission endpoint.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Quality criterion weighted at 80%; detailed assessment method is in the procurement documents. — 80%Price criterion weighted at 20%; detailed assessment method is in the procurement documents. — 20%

Lot 2

Quality criterion weighted at 80%; detailed assessment method is in the procurement documents. — 80%Price criterion weighted at 20%; detailed assessment method is in the procurement documents. — 20%

Acheteur

Localisation

Brussels, BEL

Identifiant

HADEA

Activité

General public services

Lots (2)

LOT-0001

Highly Innovative Therapeutics

Framework service lot for pathogen-targeted scalable therapeutics, innovative combination therapies, and therapeutics designed for administration through routes other than intravenous administration.

ServicesFrameworkEU fundedElectronic submission

EUR 252M

Valeur estimée

Durée

108 MONTH

Catégorie

Research

Critères d'attribution

Best price-quality ratio

Date limite

Expired Sep 02, 2026

LOT-0002

Advanced Therapeutics

Framework service lot for host-targeted scalable therapeutics, innovative combination therapies, and therapeutics designed for administration through routes other than intravenous administration.

ServicesFrameworkEU fundedElectronic submission

EUR 252M

Valeur estimée

Durée

69 MONTH

Catégorie

Research

Critères d'attribution

Best price-quality ratio

Date limite

Expired Sep 02, 2026

Détails de la procédure

Date de publication
01 Jul 2026
Langues
English, Bulgarian

Métadonnées de référence

Base juridique
32024R2509

Identifiants de référence

ID de l'appel d'offres
456593-2026

Documents (2)

Appels d'offres similaires

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy